Assessing real world dose adjustment in patients switching from intravenous immunoglobulin (IGIV) therapy to subcutaneous immunoglobulin (IGSC) 20%.

被引：0
|
作者：
Ye, Xiaolan [1 ]
Xiong, Yan [2 ]
Li-McLeod, Josephine [2 ]
机构：
[1] Baxter HealthCare, Deerfield, IL USA
[2] Baxter HealthCare, Westlake Village, CA USA
来源：
PHARMACOTHERAPY | 2014年 / 34卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
177
引用
收藏
页码：E222 / E222
页数：1
相关论文
共 50 条
  • [41] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10
  • [42] Neutropenia resulting from high-dose intravenous immunoglobulin in dermatological patients
    Stoevesandt, Johanna
    Heitmann, Johanna
    Goebeler, Matthias
    Benoit, Sandrine
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 (12): : 1394 - 1403
  • [43] Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study
    Heropolitanska-Pliszka, Edyta
    Pac, Malgorzata
    Pietrucha, Barbara
    Machura, Edyta
    Pukas-Bochenek, Anna
    Chrobak, Ewelina
    Bien, Ewa
    Malanowska, Magdalena
    Pituch-Noworolska, Anna
    Drygala, Szymon
    Kamieniak, Marta
    Kasprzak, Jakub
    Mach-Tomalska, Monika
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (10) : 1281 - 1291
  • [44] IMPROVEMENT IN TREATMENT SATISFACTION AMONG PRIMARY IMMUNODEFICIENCY PATIENTS ON AN INVESTIGATIONAL 20 % SUBCUTANEOUS IMMUNOGLOBULIN THERAPY
    Meckley, Lisa
    Ito, Diane
    Hu, Xingdi
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 245 - 245
  • [45] Safety of Intravenous Immunoglobulin (IGIV) Therapy in Patients with Probable Alzheimer's Disease (AD): a Randomized, Placebo-Controlled Clinical Study
    Gelmont, David
    Thomas, Ronald G.
    Dyck-Jones, Jacqueline A.
    Fritsch, Sandor
    Aisen, Paul
    Relkin, Norman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S53 - S54
  • [46] Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Holmgren, Johanna
    Klintman, Daniel
    Marsal, Jan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (11) : 1389 - 1401
  • [47] High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy:: a long-term follow-up
    Rasche, F. M.
    Keller, F.
    Lepper, P. M.
    Aymanns, C.
    Karges, W.
    Sailer, L. -C.
    von Mueller, L.
    Czock, D.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 146 (01): : 47 - 53
  • [48] SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD PHASE IV INTERVENTIONAL STUDY
    Rahmany, Sohail
    Young, David
    Moyses, Helen
    Gonclaves, Joao
    Latter, Sue
    Cummings, Fraser
    GUT, 2023, 72 (SUPPL_2) : A92 - A93
  • [49] Feasibility of Switching from Intravenous to Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Comparison of PATH Trial Results with Clinical Experience
    Cocito, D.
    Peci, E.
    Romagnolo, A.
    Bril, V.
    van Geloven, N.
    Hartung, H. -P.
    Lewis, R. A.
    Sobue, G.
    Lawo, J. -P.
    Mielke, O.
    Durn, B. L.
    Cornblath, D. R.
    Merkies, I. S.
    van Schaik, I. N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 373 - 373
  • [50] Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders
    Matsuda, M
    Hosoda, W
    Sekijima, Y
    Hoshi, K
    Hashimoto, T
    Itoh, S
    Ikeda, SI
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (06) : 306 - 311
12345